Stephen D. Collins
Direttore/Membro del Consiglio presso Xalud Therapeutics, Inc.
Profilo
Stephen D.
Collins is currently a Director at Xalud Therapeutics, Inc., Engage Therapeutics, Inc., and Cerebral Therapeutics, Inc. He previously held positions as President, Chief Executive Officer & Director at Biscayne Pharmaceuticals, Inc., NeuroTherapeutics Pharma, Inc., and Biscayne Neurotherapeutics, Inc. He also served as Chairman at Terpenoid Therapeutics, Inc. and Senior Director-Global Central Nervous System at Johnson & Johnson.
Additionally, he was a Director at Spinifex Pharmaceuticals Pty Ltd.
Dr. Collins has also worked as an Independent Director at Big Cypress Acquisition Corp.
from 2020 to 2021.
He has experience as a Principal at Abbott Laboratories, Case Western Reserve University, and The University of California, San Francisco.
Dr. Collins holds a doctorate degree from Case Western Reserve University and an undergraduate degree from the University of California, Berkeley.
Posizioni attive di Stephen D. Collins
| Società | Posizione | Inizio |
|---|---|---|
Xalud Therapeutics, Inc.
 Xalud Therapeutics, Inc. BiotechnologyHealth Technology Xalud Therapeutics, Inc. develops novel therapies with several promising therapeutic programs for inflammatory. The firm offers XT-101, a single dosage injection that stops disease progression, eliminates neuropathic pain, and reverses paralysis. It also researches on the applicability of XT-101 for multiple sclerosis and amyotrophic lateral sclerosis. The company was founded by John Forsayeth and Linda Watkins and is headquartered in San Francisco, CA. | Direttore/Membro del Consiglio | - |
Engage Therapeutics, Inc.
 Engage Therapeutics, Inc. BiotechnologyHealth Technology Engage Therapeutics, Inc. engages in the development of rescue therapy for uncontrolled epileptic seizures. The company was founded by Gregory T. Mayes III and Jouko Isojarvi in 2017 and is headquartered in Summit, NJ. | Direttore/Membro del Consiglio | - |
Cerebral Therapeutics, Inc.
 Cerebral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Cerebral Therapeutics, Inc. develops neurological therapeutics for uncontrolled neurological diseases. It is a clinical-stage company dedicated to improving the lives of patients living with uncontrolled neurological diseases, with an initial focus on refractory epilepsy. The firm offers long-term implanted drug-device combination therapies that bypass the blood-brain barrier to deliver optimal doses of specially formulated neurological therapeutics directly into the target region of the brain. The company was founded by Daniel J. Abrams and James P. Kelleher and is headquartered in Aurora, CO. | Direttore/Membro del Consiglio | 10/11/2020 |
Precedenti posizioni note di Stephen D. Collins
| Società | Posizione | Fine |
|---|---|---|
| BIG CYPR | Direttore/Membro del Consiglio | 22/10/2021 |
Biscayne Pharmaceuticals, Inc.
 Biscayne Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Biscayne Pharmaceuticals, Inc. develops drugs and pharmaceutical products. It offers drugs for CNS disorders such as refractory epilepsy and drug-resistant cancer. The firm also provides cancer therapies that block growth hormone-releasing hormone (GHRH) receptors. The company was founded by Andrew V. Schally and Samuel J. Reich in 2012 and is headquartered in Miami, FL. | Amministratore Delegato | - |
Spinifex Pharmaceuticals Pty Ltd.
 Spinifex Pharmaceuticals Pty Ltd. Pharmaceuticals: MajorHealth Technology Spinifex Pharmaceuticals Pty Ltd. discovers and develops new drugs for the treatment and management of pain. The firm conducts medicinal chemistry and drug discovery activities, preclinical and early-phase clinical studies before seeking a partnership with pharmaceutical company to complete clinical development, file for regulatory approval, and carry out marketing activities. The company was founded in June 2005 and is headquartered in Preston, Australia. | Direttore/Membro del Consiglio | - |
Biscayne Neurotherapeutics, Inc.
 Biscayne Neurotherapeutics, Inc. BiotechnologyHealth Technology Biscayne Neurotherapeutics, Inc. engages in the development of novel treatments for epilepsy, pain and other central nervous system (CNS) disorders. The company was founded by Samuel J. Reich on November 15, 2011 and is headquartered in Miami, FL. | Amministratore Delegato | - |
| The University of California, San Francisco | Corporate Officer/Principal | - |
Formazione di Stephen D. Collins
| Case Western Reserve University | Doctorate Degree |
| University of California, Berkeley | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| ABBOTT LABORATORIES | Health Technology |
| JOHNSON & JOHNSON | Health Technology |
| Aziende private | 10 |
|---|---|
Terpenoid Therapeutics, Inc.
 Terpenoid Therapeutics, Inc. Medical DistributorsDistribution Services Terpenoid Therapeutics, Inc. operates as a biotechnology company focuses on anti-cancer therapeutics. The firm engages in creating, testing, and developing novel drug candidates using cutting-edge technologies. It is focused on discovering small molecule inhibitors of geranylgeranyl diphosphate synthase, a novel target with applicability towards cancer and other indication. The company was founded by Andrew J. Wiemer, Jeffery D. Neighbors, David F. Wiemer and Raymond J. Hohl in September 2005 and is headquartered in Coralville, IA. | Distribution Services |
Biscayne Pharmaceuticals, Inc.
Biscayne Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Biscayne Pharmaceuticals, Inc. develops drugs and pharmaceutical products. It offers drugs for CNS disorders such as refractory epilepsy and drug-resistant cancer. The firm also provides cancer therapies that block growth hormone-releasing hormone (GHRH) receptors. The company was founded by Andrew V. Schally and Samuel J. Reich in 2012 and is headquartered in Miami, FL. | Health Technology |
OVATION Pharmaceuticals, Inc.
 OVATION Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OVATION Pharmaceuticals, Inc. develops, manufactures and markets pharmaceuticals. It focuses on central nervous system, hematology or oncology and hospital-based therapies. The company was founded by Jeffrey S. Aronin in 2000 and is headquartered in Deerfield, IL. | Health Technology |
NeuroTherapeutics Pharma, Inc.
 NeuroTherapeutics Pharma, Inc. Pharmaceuticals: MajorHealth Technology NeuroTherapeutics Pharma, Inc. is a biopharmaceutical company focused on developing therapies for diseases associated with central nervous system hyper-excitability. It is developing compounds that decrease or eliminate aberrant excitatory discharges by working through a new mechanism of action. The firm's proprietary molecules target a novel molecular site that will create a pipeline of potential new treatments for multiple CNS disorders. The company's lead compound, NTP-2014, has exhibited excellent efficacy results in multiple preclinical models of epilepsy, acute and neuropathic pain. NeuroTherapeutics Pharma was founded in 2006 and is headquartered in Chicago, IL. | Health Technology |
Spinifex Pharmaceuticals Pty Ltd.
Spinifex Pharmaceuticals Pty Ltd. Pharmaceuticals: MajorHealth Technology Spinifex Pharmaceuticals Pty Ltd. discovers and develops new drugs for the treatment and management of pain. The firm conducts medicinal chemistry and drug discovery activities, preclinical and early-phase clinical studies before seeking a partnership with pharmaceutical company to complete clinical development, file for regulatory approval, and carry out marketing activities. The company was founded in June 2005 and is headquartered in Preston, Australia. | Health Technology |
Biscayne Neurotherapeutics, Inc.
Biscayne Neurotherapeutics, Inc. BiotechnologyHealth Technology Biscayne Neurotherapeutics, Inc. engages in the development of novel treatments for epilepsy, pain and other central nervous system (CNS) disorders. The company was founded by Samuel J. Reich on November 15, 2011 and is headquartered in Miami, FL. | Health Technology |
Xalud Therapeutics, Inc.
Xalud Therapeutics, Inc. BiotechnologyHealth Technology Xalud Therapeutics, Inc. develops novel therapies with several promising therapeutic programs for inflammatory. The firm offers XT-101, a single dosage injection that stops disease progression, eliminates neuropathic pain, and reverses paralysis. It also researches on the applicability of XT-101 for multiple sclerosis and amyotrophic lateral sclerosis. The company was founded by John Forsayeth and Linda Watkins and is headquartered in San Francisco, CA. | Health Technology |
Engage Therapeutics, Inc.
Engage Therapeutics, Inc. BiotechnologyHealth Technology Engage Therapeutics, Inc. engages in the development of rescue therapy for uncontrolled epileptic seizures. The company was founded by Gregory T. Mayes III and Jouko Isojarvi in 2017 and is headquartered in Summit, NJ. | Health Technology |
Cerebral Therapeutics, Inc.
Cerebral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Cerebral Therapeutics, Inc. develops neurological therapeutics for uncontrolled neurological diseases. It is a clinical-stage company dedicated to improving the lives of patients living with uncontrolled neurological diseases, with an initial focus on refractory epilepsy. The firm offers long-term implanted drug-device combination therapies that bypass the blood-brain barrier to deliver optimal doses of specially formulated neurological therapeutics directly into the target region of the brain. The company was founded by Daniel J. Abrams and James P. Kelleher and is headquartered in Aurora, CO. | Commercial Services |
Big Cypress Acquisition Corp.
 Big Cypress Acquisition Corp. Financial ConglomeratesFinance Big Cypress Acquisition Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination. The company was founded on November 12, 2020 and is headquartered in Miami Beach, FL. | Finance |
- Borsa valori
- Insiders
- Stephen D. Collins
